Enterprise Value

1.299B

Cash

75.64M

Avg Qtr Burn

-10.28M

Short % of Float

26.43%

Insider Ownership

52.41%

Institutional Own.

23.71%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NGENLA® Somatrogon Details
Pediatric growth hormone deficiency

Approved

Quarterly sales

Approved

Quarterly sales

Phase 2

Update

SAR441236 Details
Human immunodeficiency virus

Phase 1

Update

Phase 1

Initiation

Failed

Discontinued